[go: up one dir, main page]

WO2001085789A3 - Extracellular domain of ryk protein for regulating angiogenesis - Google Patents

Extracellular domain of ryk protein for regulating angiogenesis Download PDF

Info

Publication number
WO2001085789A3
WO2001085789A3 PCT/US2001/015043 US0115043W WO0185789A3 WO 2001085789 A3 WO2001085789 A3 WO 2001085789A3 US 0115043 W US0115043 W US 0115043W WO 0185789 A3 WO0185789 A3 WO 0185789A3
Authority
WO
WIPO (PCT)
Prior art keywords
ryk
extracellular domain
diseases
regulating angiogenesis
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/015043
Other languages
French (fr)
Other versions
WO2001085789A2 (en
Inventor
Steve Roczniak
Nathalie A Dubois-Stringfellow
Alya Zolotorev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Priority to CA002408349A priority Critical patent/CA2408349A1/en
Priority to US10/275,589 priority patent/US20040023864A1/en
Priority to AU2001261343A priority patent/AU2001261343A1/en
Priority to EP01935233A priority patent/EP1287121A2/en
Priority to JP2001582388A priority patent/JP2004527206A/en
Publication of WO2001085789A2 publication Critical patent/WO2001085789A2/en
Publication of WO2001085789A3 publication Critical patent/WO2001085789A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Ryk protein was found to have a novel activity in regulating angiogenesis. New variant Ryk proteins were constructed that were useful in modulating the capillary forming activity of endothelial cells. Variant Ryk proteins, may be employed as therapeutics in diseases such as cancer, wound healing, diabetic retinopathies, macular degeneration, and cardiovascular diseases, and other diseases or clinical conditions where angiogenesis is relevant to the causation or treatment of the disease.
PCT/US2001/015043 2000-05-10 2001-05-09 Extracellular domain of ryk protein for regulating angiogenesis Ceased WO2001085789A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002408349A CA2408349A1 (en) 2000-05-10 2001-05-09 Method of regulating angiogenesis unsing ryk protein
US10/275,589 US20040023864A1 (en) 2001-05-09 2001-05-09 Method of regulating angiogenesis using ryk protein
AU2001261343A AU2001261343A1 (en) 2000-05-10 2001-05-09 Method of regulating angiogenesis using ryk protein
EP01935233A EP1287121A2 (en) 2000-05-10 2001-05-09 Extracellular domain of ryk protein for regulating angiogenesis
JP2001582388A JP2004527206A (en) 2000-05-10 2001-05-09 Method for regulating angiogenesis using Ryk protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10
US09/568,783 2000-05-10

Publications (2)

Publication Number Publication Date
WO2001085789A2 WO2001085789A2 (en) 2001-11-15
WO2001085789A3 true WO2001085789A3 (en) 2002-05-16

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/015043 Ceased WO2001085789A2 (en) 2000-05-10 2001-05-09 Extracellular domain of ryk protein for regulating angiogenesis

Country Status (13)

Country Link
EP (1) EP1287121A2 (en)
JP (1) JP2004527206A (en)
AR (1) AR028424A1 (en)
AU (1) AU2001261343A1 (en)
CA (1) CA2408349A1 (en)
CO (1) CO5300464A1 (en)
DO (1) DOP2001000164A (en)
EC (1) ECSP014068A (en)
GT (1) GT200100079A (en)
PE (1) PE20011218A1 (en)
SV (1) SV2002000442A (en)
UY (1) UY26696A1 (en)
WO (1) WO2001085789A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471934A2 (en) * 2002-02-06 2004-11-03 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition including Afflipersept, Folinic Acid, 5- Fluorouracil (5- Fu) and Irenosetan (FOLFIRI)
TR201909951T4 (en) 2014-07-18 2019-07-22 Sanofi Sa A method for predicting the outcome of aflibercept treatment of a patient suspected of having cancer.
US20250027945A1 (en) * 2021-08-18 2025-01-23 The Regents Of The University Of California Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023429A1 (en) * 1992-05-11 1993-11-25 Ludwig Institute For Cancer Research Receptor-type tyrosine kinase-like molecules
EP0854185A2 (en) * 1994-12-23 1998-07-22 Ludwig Institute For Cancer Research Assay receptor proteins and ligands
WO1999064589A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Human receptor tyrosine kinase
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023429A1 (en) * 1992-05-11 1993-11-25 Ludwig Institute For Cancer Research Receptor-type tyrosine kinase-like molecules
EP0854185A2 (en) * 1994-12-23 1998-07-22 Ludwig Institute For Cancer Research Assay receptor proteins and ligands
WO1999064589A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Human receptor tyrosine kinase
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HALFORD MICHAEL M ET AL: "Genomic structure and expression of the mouse growth factor receptor related to tyrosine kinases (Ryk).", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 11, 12 March 1999 (1999-03-12), pages 7379 - 7390, XP002189270, ISSN: 0021-9258 *
SHAWVER ET AL: "Receptor tyrosine kinases as targets for inhibition of angiogenesis", DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD, GB, vol. 2, no. 2, February 1997 (1997-02-01), pages 50 - 63, XP002118090, ISSN: 1359-6446 *
TAMAGNONE LUCA ET AL: "The human ryk cDNA sequence predicts a protein containing two putative transmembrane segments and a tyrosine kinase catalytic domain.", ONCOGENE, vol. 8, no. 7, 1993, pages 2009 - 2014, XP002189269, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
CO5300464A1 (en) 2003-07-31
UY26696A1 (en) 2001-12-28
AR028424A1 (en) 2003-05-07
AU2001261343A1 (en) 2001-11-20
EP1287121A2 (en) 2003-03-05
PE20011218A1 (en) 2002-02-01
DOP2001000164A (en) 2002-05-15
WO2001085789A2 (en) 2001-11-15
ECSP014068A (en) 2002-02-25
GT200100079A (en) 2001-12-31
SV2002000442A (en) 2002-07-03
JP2004527206A (en) 2004-09-09
CA2408349A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
AU5404399A (en) Topical application products
EP1295893A4 (en) GINSENOSIDES FOR PROMOTING SKIN WEBERENEGENERATION
AU2002233288A1 (en) Combined use of Enzyme Inhibitors and Pharmaceutical Preparations thereof for the Treatment and Prophylaxis of Arteriosclerosis, for the Treatment and Prevention of Allergic Reactions of Type I According to the Gell and Coombs Classification, and for the Treatment and Prevention of Dermatological Diseases Associated with FO
DE69812151D1 (en) LACTIC ACID BACTERIA CONTAINING PRODUCT AND PRODUCTION
ATE385806T1 (en) FUSION PROTEINS
WO2000027819A3 (en) Antrhranilic acid amides and the use thereof as medicaments
EA200400482A1 (en) KERATINOCYCES SUITABLE FOR APPLICATION AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF THE RAS
PT749317E (en) THERAPEUTIC APPLICATIONS OF DIMERIC PRODUCTS OF PERMEABILITY INDUCED BACTERICID PROTEINS
NO971341D0 (en) Promoter for receptor tyrosine kinase TIE
EP1172084A3 (en) Cosmetic and dermatologic composition to eliminate sebum
WO2001085789A3 (en) Extracellular domain of ryk protein for regulating angiogenesis
ITRM970238A0 (en) USE OF THE NERVE GROWTH FACTOR IN THE PRESERVATION OF CORNEAS IN CULTURE, IN THE PRODUCTION OF CORNEAL AND CONJUNCTIVAL TISSUES IN VITRO AND IN THE THERAPY OF CORNEAL AND CONJUNCTIVAL DISEASES
AU7538700A (en) 5-hydroxysapogenin derivatives with anti-dementia activity
WO1997023507A3 (en) New form of amphiregulin, methods for producing and using the same and compositions comprising the same
AU2001232736A1 (en) Protein c derivatives
WO2001045738A3 (en) Use of heat shock proteins to enhance production of chemokines by a cell
WO2001074852A3 (en) Protein having activity as an angiogenesis modulator
DE60107444D1 (en) USE OF A POLLEN EXTRACT CONTAINER FOR THE TREATMENT OF EDEMS
WO2002004521A3 (en) Proteins with integrin-like activity
WO2003000222A3 (en) Cosmetic preparation with anti-wrinkle action
WO2002030443A3 (en) Regulation of human skin healing
WO2001085200A3 (en) Recombinant human cln2 protein and methods of its production and use
DE59805246D1 (en) TISSUE FACTOR INFLUENCING VASOCULAR FORMATION
AU2001249267A1 (en) Methods and compositions for elucidating protein expression profiles in cells
WO2000050047A3 (en) Composition for the treatment of psoriasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2408349

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001935233

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001935233

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10275589

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001935233

Country of ref document: EP